The aim of this study was to define the most useful index of expressing bronchodilator response and to distinguish between asthma and COPD.
Introduction
The measurement of spirometric data before and after inhaling a bronchodilator is a commonly ordered pulmonary function test in clinical and research settings. Despite its well-known limitations, it is one of the most useful criteria for asthma diagnosis. Additionally, most clinical trials define 'reversible' vs. 'non-reversible' airway obstruction depending on bronchodilator response, which theoretically determines homogeneous study samples. However, there are no uniformly accepted criteria for defining a 'significant' response (1, 2 societies nor universally accepted, it is a very common means of expression. An increase in FEVI 215% was the most popular definition of a positive bronchodilator response found in a review of the asthma and chronic obstructive pulmonory disease (COPD) literature and some medical settings (3). However, this criterion has recently been challenged due to an inadequate ability to separate diagnostically asthma and COPD patients (4) and mainly because of the generation of a much greater proportion of responsive patients (probably false) among patients with very low initial FEVl (5-7). On the other hand, expressing change as an absolute value (for instance, 200 ml) may theoretically require values impossible to achieve for patients with very low FEV1, thus creating a falsely high proportion of non-responsive tests. Choosing one or the other criterion may result in a different classification of a relevant number of patients (5) .
These difficulties have provoked increasing interest in exploring other ways to express bronchodilator response (8, 9) . The characteristics of an ideal index should be maximal independence of the pre-bronchodilator FEVl value, greatest power to discriminate asthma and COPD Q 1999 HARC~LIRT PUBLISHERS LTD and the reproducibility of bronchodilator response. We have examined the different ways of expressing bronchodilator response in patients with previously known disease (asthma and COPD) in order to define their dependence on initial FEVr and their efficacy to separate patients with asthma from patients with COPD.
Material and Methods
Two hundred patients with airway obstruction were studied during a routine visit in our chest clinic (142 asthmatics, 58 COPD). They were included in the study if they had a previously diagnosed airway obstructive disease and a present baseline spirometry with a FEVi/FVC relationship 1.64 SEE below the predicted value or lower. All COPD patients showed FEV, values lower than 10% of predicted value. To test the power of each index to discriminate between COPD and asthma patients, a comparison was performed studying the subgroup of asthmatics with FEVi lower than 55% of predicted value (n = 61) in order to match COPD and asthma patients for baseline lung function. Patients with other chronic respiratory diseases (occupational lung disorder, bronchiectasis, interstitial lung disease, tuberculosis and cancer), previous thoracic surgery, heart failure or any other condition able to interfere with an adequate expiratory manoeuvre or a correct classification of asthma or COPD were excluded. A standardized history of respiratory symptoms was obtained. Patients were classified as asthmatics when they reported attacks of breathlessness and wheeze according ATS criteria and were non-smokers. All the asthmatic patients had been followed at our hospital for some years. All of them had at least two of the following criteria: 1. history of symptoms since childhood or adolescence; 2. symptomatic-free periods of longer than 3 months; 3. spontaneous variations of FEVi during the year of over 20% of baseline value; 4. a histamine challenge test with a PC& under 8 mg ml-'. Patients were classified as COPD when they were heavy current or ex-smokers with no history of asthma, reporting chronic cough with sputum. To avoid misclassification, patients with history suggesting asthma but who were smokers and patients with history suggesting COPD but who were not smokers were not included, even though a small group of asthmatics can be smokers and a few COPD patients are not ex-or current smokers. Patients not clearly classified as one or the other group were not included.
Patients under current treatment with systemic steroids were excluded. All patients with asthma were receiving inhaled steroids and bronchodilators following international stepwise guidelines. COPD patients were not receiving inhaled steroids but only regular treatment with inhaled bronchodilators and theophylline during symptomatic periods. All spirometric tests were performed in the seated position by the same two technicians according to standardized guidelines. Calibration was checked every day. Patients were requested to abstain from inhaled steroids, theophylline and bronchodilators for at least 12 h before the study. FEVi and FVC were assessed at least three times with a dry wedge bellows spirometer (Vitalo- In order to investigate the dependence of each index on baseline FEV,, linear regression analysis of the bronchodilator response was applied, taking the Pearson correlation coefficient as a measure of the extent of the relationship. The two-tailed t-test for unpaired samples was applied to compare group means.
The sensitivity and specificity of a bronchodilator response to salbutamol in separating patients with asthma and COPD were calculated applying most commonly published values (dabs 200 ml, Ainit 15%) or values derived from confidence intervals previously obtained in studies with placebo in our pulmonary function laboratory (A % pred 9%, A %max 50%) (10). The predictive value for a positive test [true positives/(true positives + false positives)] and the predictive value for a negative test [true negatives/(true negatives + false negatives)] were calculated on the basis of an arbitrarily chosen clinical pre-test probability of asthma of 30 and 70%. The likelihood ratio (sensitivity/l -specificity), which reflects the ability of a test to discriminate between subjects with asthma or COPD was also calculated for each index (11) . For this analysis, two different samples were studied: 1. the whole sample of asthmatics vs. COPD and 2. the sample of asthmatics with FEVt lower than 55% of predicted value vs. COPD.
Results
Of the 200 patients, 142 were classed as asthmatic (mean age 55.4* 19.0 years, 68 women) and 58 as COPD (mean age 67.3 + 7.0 years, 12 women). Baseline FEVi in asthma patients was 1.57 kO.76 1 (59.4f 19.1 % of predicted) and in patients with COPD 1.01 kO.34 1 (39.7 * 14.7% of predicted). CVF was 2.59 ho.87 1 (80.6 +20.2% of predicted) in asthmatics and 1.23 + 0.55 1 (60.2 i 13.7% of predicted) in COPD. Of the COPD patients 23% were current smokers and 77% ex-smokers (68.3 i 36.5 pack years). Sixty-one asthmatic patients showed an FEVi lower than 55% of predicted (mean FEVi 41.9 + 8.7%).
RELATIONSHIP BETWEEN BASELINE FEVl AND BRONCHODILATOR RESPONSE
There was no relationship between dabs and pre-Bd FEV, either in asthmatics or in COPD. Changes expressed as A%red, did not show correlation with pre-Bd FEV, in asthmatics or in COPD (Table 1) .
On the other hand, the bronchodilating response expressed as a percentage of the initial value was dependent on pre-Bd FEVr in asthmatics, although not in COPD. Bronchodilator responsiveness expressed as a percentage of the maximal possible response tends to infinity when pre-Bd FEVl is equal or higher than predicted, therefore it cannot be calculated in these situations. The correlation coefficient was calculated excluding such cases, although the scattering of A%max was very important. A%max was dependent on pre-Bd FEVr as % predicted in asthmatics and COPD (Table 1 ). When the sample was considered as a whole (asthma+COPD) (n=200) dabs (r=O.O3, P=n.s.) ( Fig. 1 ) and A %pred (r = 0.02, P = n.s.) (Fig. 2) were still independent of pre-Bd FEVr. However A% init (v = 0.37, P< 0,001) ( Fig. 3) Fig. 4 ). However, if only patients with reduced FEVr (lower than 55% of predicted) were considered, all indices reached statistical significance in separating asthma and COPD (Table 2 , Fig. 4) . Bronchodilator response did not show a sensitivity higher than 85% to establish asthma diagnosis for any index. The lowest specificity was obtained with A% init (50.0%) ( A %max had very low values of sensitivity (19.0%) and a low predictive value for a negative test (Tables 3 and 4) . The most powerful indices for discriminating between asthma and COPD were dabs and A%pred as they showed The clinical usefulness of each index is highly dependent on clinical pre-test probability of asthma. A%init shows the worst results of predictive values for a positive or negative test in most circumstances. In patients with high clinical pre-test, the presence of a positive reponse expressed as A%max may be a very specific diagnostic index. Bold type indicates significant difference.
Discussion
This study demonstrates that expressing bronchodilator response in one of the most popular ways (increase in FEVi as a percentage of baseline FEVi) has important disadvantages: it is strongly dependent on the pre-bronchodilator FEVr, does not reveal significant differences between asthma and COPD patients and shows the weakest power to discriminate between these two conditions.
In order to define reversibility to bronchodilator, three factors should be considered: 1. which will be the applied indices? (FEVi, FVC, FEFzTm7s?); 2. which will be the chosen way of expressing this response? and 3. which will be the cut-off limits to define a positive response?
Firstly, FEVi was better than other commonly used tests for evaluating bronchodilating drugs (5, 12) . Secondly, the cut-off limits of a positive response may be defined from studies using patient samples to determine confidence intervals for spontaneous variability (13) or placebo response (10, 14) , or may be calculated from the response to bronchodilator in normal subjects (1.5). Taking into account that the distribution of bronchodilator response in any of those popu!ations is continuous and unimodal, any definition of the 'cut-off level for a positive response will be arbitrary.
The chosen values for this study were derived from confidence intervais for response to placebo obtained at our pulmonary function laboratory (lo), which are similar to currently published values (1, 16) .
Finally, if the two most commonly used indices for expressing response (dabs and do&nit) are analysed, it seems obvious that a change of 200 ml may be a small variation in a baseline FEVi of 2.5 1 (< lo%), while it may be almost impossible to achieve for a very low baseline FEVi, e.g. 0.4 1 (50%). At the same time, a change of 15% in initial value may be a very low value in the second example (60 ml), with equivocal clinical significance and even the possibility of under-resolution of the spirometry equipment.
The number of patients classed differently according to the different criteria is not small (12% of asthmatics in a study population) (5) and is important in defining which index is more accurate.
An index with a greater independence of baseline FEVi increases the comparability between different subjects and also between tests with different baseline FEVi in the same subject (5, 17) . According to our results in patients with asthma, only dabs and A%pred were independent of preBd FEV,, while in COPD patients only A%max showed a strong dependence on the baseline FEVi value. These results in COPD patients contrast with data obtained by Dompeling et al. (17) , where A%init was very dependent on pre-Bd FEVi. Differences in patient selection may explain this disagreement. Dompeling's patients showed a much lower degree of bronchial obstruction than ours (baseline FEVi 77 + 18% vs. 39.7 + 14.7% predicted) and a higher response to bronchodilator (dabs 0.26& 0.14 1 vs. 0.16 + 0.14 1). The higher homogeneity of our sample (and perhaps the smaller number, n = 58 vs. 111) may be the reason for the absence of the dependence showed by Dompeling et al. (17) . Despite this difference, our data and results from other authors (9, 17) strongly suggest that the most popular index (do/&nit) is highly dependent on the baseline value in asthma (8) or in a non-selected patient population (9) (v for our population as a whole =0.33, P= <O.OOl). This fact is remarkably relevant when defining bronchodilator response in clinical trials or in patients in different clinical situations. If an inclusion criterion is a predetermined level of bronchodilator response expressed as A%init (which is very common) (1819) this will select patients with a more severe pre-bronchodilator airway obstruction. On the other hand, if the sample is composed of more severely affected patients, the response to bronchodilator as a percentage of initial value will be magnified due only to the chosen criterion. Similarly, the response to any bronchodilator in a patient who has experienced great change in his or her baseline FEVi may be falsely interpreted as different. This potential error would be avoided if response were expressed as dabs. Finally, in light of the strong dependence of A%init, the prognostic significance of bronchodilator responsiveness in COPD patients should be reconsidered. A worse prognosis for patients with higher reversibility (expressed as A%init) has been reported (20, 21) . However, is this really the influence of reversibility or solely due to the selection of more severe patients who show a greater response when expressed as A%init? (22) . Interestingly, when Postma et al. (23) assessed response to bronchodilator using A% (predinitial), a higher reversibility was a favourable prognostic criterion.
It is remarkable that several different studies which have analysed the dependence of bronchodilator response on pre-bronchodilator values, while in accord over the strong dependence of A%init, show very different results regarding other methods of expressing reversibility (Table 5) . Obviously, the composition of the sample is critical in determining such relationships. This is very important in designing clinical trials and the chosen method of expressing bronchodilator response should be assessed in that particular sample to exclude dependence on baseline FEVi.
Even when advantages of dabs and A%pred in separating positive and negative responses are clear, the prognostic significance of these indices in evaluating the long-term outcome has not been assessed.
Reversibility with a bronchodilator is also a criterion for differential diagnosis between asthma and COPD. Even when inflammation and not bronchodilator response distinguishes between the two disorders, the degree of bronchial responsiveness is a commonly used criterion to separate asthma and COPD in clinical practice and inclusion in clinical trials. In this study, none of the indices resulted in a good differentiation between the two disorders. This is in agreement with previous studies, indicating that up to 23% of asthmatics showed a non-responsive spirometry (5) . The most powerful indices found to separate asthma and COPD in this population were dabs and A%pred, which showed the highest likelihood ratios (dabs, 2.23 and A%pred, 2.03) and thus the best combination of sensitivity, and specificity, compared to A%init (likelihood ratio 1.28). When analysing the discriminative value of each index solely by considering differences in group means, all indices reached a statistically significant difference if only patients with reduced FEVi were considered. However, in a more complete analysis, the sensitivity, the specificity and likelihood ratios were not substantially modified by excluding patients with nearnormal baseline FEVi . Published studies disagree considerably on this point. While Nicklaus (6), assessing only A%init, showed a strong discriminative power for bronchodilator response, Brand et al. (8) found this method to be a poor diagnostic criterion. This disagreement may again be explained by different population compositions and methods of analysis. Discriminative power may be evaluated using group mean differences (17) or by including sensitivity and specificity calculations (8, 24) and, even when the same method is used, different inclusion criteria and doses of bronchodilator may influence the final results. It is remarkable that, in the present study, even the best indices were not sensitive for asthma diagnosis. It is important to remember that clinical background is critically significant in defining predictive values and thus to delimit the increase in diagnostic power using each index. With a low pre-test probability of asthma (30%), even the best indices in this study showed low predictive values for a positive test, however these reached clinical relevance with higher pre-test probabilities. This emphasizes that, in a clinical setting, the occurrence of a negative test does not exclude the presence of asthma, even when a better diagnosis may be obtained by dabs or A%pred.
We conclude that: 1. in clinical practice A%init is a poor diagnostic tool to differentiate asthma from COPD; 2. in patients with a previously known diagnosis, A%init overestimates the response to bronchodilator in subjects with very low baseline FEVi; and 3. in clinical trials studying reversibility, the chosen index should be assessed to exclude dependence on the initial FEVi. The expression which correlates best with clinical improvement after long-term treatment has not yet been defined, therefore the inclusion of different indices for expressing bronchodilator response in clinical trials studying the effects of long-term inhalational therapy would be extremely useful.
